PMC4276356_01
CT scans depicting the preoperative aspect of the lesion (a), the necrosis obtained after surgery and RFA (b), and the positions of the electrodes during percutaneous RFA performed after surgery (c).
CRIRA2014-697480.001.jpg
PMC4276356_01_CRIRA2014-697480.001.jpg
fig1
The patient underwent four cycles of cisplatin, doxorubicin, vincristine, and cyclophosphamide, with only a slight reduction of the mass (Figure 1(a)). Before closing the thorax, an RFA of the residual tumor was performed with a needle monopolar electrode, as we previously described, positioned in the centre of the lesion, and a partial necrosis of the mass was achieved (Figure 1(b)). A further percutaneous RFA was carried out two months later, positioning the electrode in an area adjacent to the central necrosis (Figure 1(c)); after this intervention, no tumoral enhancement within the lesion was detected (Figure 2(a)).
CT scans showing the local conditions of the patient one month after percutaneous RFA (a) and NMR depicting complete response 36 months after treatment (b).
CRIRA2014-697480.002.jpg
PMC4276356_01_CRIRA2014-697480.002.jpg
fig2
A further percutaneous RFA was carried out two months later, positioning the electrode in an area adjacent to the central necrosis (Figure 1(c)); after this intervention, no tumoral enhancement within the lesion was detected (Figure 2(a)). A complete response was obtained, as shown by a nuclear magnetic resonance (NMR) scan performed 36 months later (Figure 2(b)).